Posters

Long-term follow-up of biodegradable collagen matrix (ologen®) implant and CLAU for calcified scleral necrosis after pterygium excision

Poster Details

First Author: S.Lee SOUTH KOREA

Co Author(s):    E. Cho   W. Gu           

Abstract Details

Purpose:

To introduce a new biodegradable material (Ologen® Collagen Matrix: OCM) for repairing of calcified scleral thinning instead of preserved scleral tissue and to evaluate the long-term outcomes of OCM for ocular surface reconstruction surgery.

Setting:

Department of Ophthalmology, Yeungnam University Hospital, Daegu, Korea

Methods:

Two cases (M/72, F/70) of marked scleral thinning after pterygium excision with topical MMC were included in this study. Conjunctival limbal autograft (CLAU) and OCM graft at scleral thinning area was performed in both patients. OCM was cut by same size of scleral thinning area using biopsy punch and sutured with recipient sclera using 10-0 nylon interrupted sutures. Free conjunctival limbal autograft was harvested with punch biopsy 1 mm larger in radius than the piece of OCM. Previous sutured OCM bed was covered with CLAU and the graft was secured with interrupted sutures of 10-0 nylon. Long-term follow-ups over than one-year were performed in both patients.

Results:

Reepithelialization of the ocular surface was observed within 3~6 days after surgery. All patients experienced loss of ocular pain, loss of inflammation, rapid stabilized ocular surface, and improvement in visual acuity. All of the OCM graft with CLAU remained intact and provided good healthy ocular surface. And recurrence of epithelial defect and scleral thinning was not observed over than a one-year follow-up period in each patient.

Conclusions:

When scleral surface defects was present, especially in scleromalacia or scleral necrosis after surgical excision of pterygium, the OCM graft with CLAU is highly recommended for good clinical outcomes and low recurrence rates. With clinical results of surgical treatment in this study, new biodegradable material of Ologen® Collagen Matrix qualifies as a new treatment alternative for scleral tissue or amniotic membrane for ocular surface reconstruction. FINANCIAL INTEREST: NONE